NURS 6521 MIDTERM EXAM
ADVANCED PHARMACOLOGY
QUESTIONS AND ANSWERS 100%
VERIFIED BY EXPERTS. 2026/2027 :
WALDEN UNIVERSITY
1. A patient with chronic kidney disease (CKD) requires an adjustment in drug dosing. Which
pharmacokinetic phase is most affected by this condition?
A. Absorption
B. Distribution
C. Excretion
D. Metabolism
Answer: C
Conceptual Explanation: Excretion is the primary pharmacokinetic phase affected by
renal impairment, as the kidneys are the main organ responsible for removing drugs and
their metabolites from the body.
2. Which of the following describes the ‘first-pass effect’ in pharmacology?
A. The metabolic breakdown of an oral drug in the liver before it reaches systemic
circulation.
,B. The rapid distribution of drugs to highly vascularized organs.
C. The initial binding of a drug to plasma proteins like albumin.
D. The time it takes for a drug to reach its peak therapeutic level.
Answer: A
Conceptual Explanation: The first-pass effect occurs when drugs taken orally are
absorbed in the GI tract and carried to the liver via the portal vein, where they are
metabolized before reaching the rest of the body.
3. When prescribing a drug with a narrow therapeutic index, the Advanced Practice Nurse
(APN) knows that:
A. The difference between a therapeutic dose and a toxic dose is small.
B. The drug is very safe and requires little monitoring.
C. The drug has a very long half-life and stays in the body for weeks.
D. The drug must only be administered via intravenous infusion.
Answer: A
Conceptual Explanation: A narrow therapeutic index indicates that there is a small
margin of safety between the dose that produces a beneficial effect and the dose that
causes toxicity.
, 4. An elderly patient is prescribed a lipid-soluble medication. How does the increase in body
fat associated with aging affect the distribution of this drug?
A. It increases the drug’s half-life.
B. It decreases the volume of distribution.
C. It causes the drug to be excreted more rapidly.
D. It leads to higher peak plasma concentrations.
Answer: A
Conceptual Explanation: In elderly patients, increased body fat serves as a reservoir for
lipid-soluble drugs, leading to a larger volume of distribution and a prolonged half-life.
5. A patient is taking a drug that is a known CYP450 enzyme inducer. If they start another
drug metabolized by the same enzyme, what is the likely result?
A. Decreased serum levels of the second drug.
B. Increased serum levels of the second drug.
C. No change in the metabolism of the second drug.
D. Immediate toxic reaction to the first drug.
Answer: A
Conceptual Explanation: Enzyme inducers increase the rate of drug metabolism, which
typically leads to lower serum levels and decreased therapeutic effects of the substrate
drug.
ADVANCED PHARMACOLOGY
QUESTIONS AND ANSWERS 100%
VERIFIED BY EXPERTS. 2026/2027 :
WALDEN UNIVERSITY
1. A patient with chronic kidney disease (CKD) requires an adjustment in drug dosing. Which
pharmacokinetic phase is most affected by this condition?
A. Absorption
B. Distribution
C. Excretion
D. Metabolism
Answer: C
Conceptual Explanation: Excretion is the primary pharmacokinetic phase affected by
renal impairment, as the kidneys are the main organ responsible for removing drugs and
their metabolites from the body.
2. Which of the following describes the ‘first-pass effect’ in pharmacology?
A. The metabolic breakdown of an oral drug in the liver before it reaches systemic
circulation.
,B. The rapid distribution of drugs to highly vascularized organs.
C. The initial binding of a drug to plasma proteins like albumin.
D. The time it takes for a drug to reach its peak therapeutic level.
Answer: A
Conceptual Explanation: The first-pass effect occurs when drugs taken orally are
absorbed in the GI tract and carried to the liver via the portal vein, where they are
metabolized before reaching the rest of the body.
3. When prescribing a drug with a narrow therapeutic index, the Advanced Practice Nurse
(APN) knows that:
A. The difference between a therapeutic dose and a toxic dose is small.
B. The drug is very safe and requires little monitoring.
C. The drug has a very long half-life and stays in the body for weeks.
D. The drug must only be administered via intravenous infusion.
Answer: A
Conceptual Explanation: A narrow therapeutic index indicates that there is a small
margin of safety between the dose that produces a beneficial effect and the dose that
causes toxicity.
, 4. An elderly patient is prescribed a lipid-soluble medication. How does the increase in body
fat associated with aging affect the distribution of this drug?
A. It increases the drug’s half-life.
B. It decreases the volume of distribution.
C. It causes the drug to be excreted more rapidly.
D. It leads to higher peak plasma concentrations.
Answer: A
Conceptual Explanation: In elderly patients, increased body fat serves as a reservoir for
lipid-soluble drugs, leading to a larger volume of distribution and a prolonged half-life.
5. A patient is taking a drug that is a known CYP450 enzyme inducer. If they start another
drug metabolized by the same enzyme, what is the likely result?
A. Decreased serum levels of the second drug.
B. Increased serum levels of the second drug.
C. No change in the metabolism of the second drug.
D. Immediate toxic reaction to the first drug.
Answer: A
Conceptual Explanation: Enzyme inducers increase the rate of drug metabolism, which
typically leads to lower serum levels and decreased therapeutic effects of the substrate
drug.
